Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease. (Q37869193)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21521250 AND SRC:MED&resulttype=core&format=json

29 January 2020

review article

1 reference

title

Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21521250 AND SRC:MED&resulttype=core&format=json

inflammatory bowel diseases

29 January 2020

main subject

0 references

0 references

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21521250 AND SRC:MED&resulttype=core&format=json

29 January 2020

author name string

S G Veerappan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21521250 AND SRC:MED&resulttype=core&format=json

29 January 2020

C A O'Morain

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21521250 AND SRC:MED&resulttype=core&format=json

29 January 2020

J S Daly

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21521250 AND SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

English

0 references

publication date

26 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21521250 AND SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

29 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21521250 AND SRC:MED&resulttype=core&format=json

29 January 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21521250 AND SRC:MED&resulttype=core&format=json

29 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21521250 AND SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

1261-1272

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21521250 AND SRC:MED&resulttype=core&format=json

Fracture risk in patients with celiac Disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark

29 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

A controlled study of bone mineral density in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Sex hormone status and bone metabolism in men with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Frequency of glucocorticoid resistance and dependency in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

The molecular mechanism of osteoclastogenesis in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Effects of interleukin-1 beta and tumor necrosis factor-alpha on osteoblastic expression of osteocalcin and mineralized extracellular matrix in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Evaluation of bone mineral density in inflammatory bowel disease: current safety focus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Maintenance Infliximab Treatment Is Associated with Improved Bone Mineral Density in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Adalimumab: in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Tumor necrosis factor-? mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X

Treatment With Infliximab Is Associated With Increased Markers of Bone Formation in Patients With Crohn??s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04667.X